Dave Wustrow
About Dave Wustrow
David Wustrow, Ph.D. - Senior Vice President at RAPT Therapeutics
David Wustrow, Ph.D., is the Senior Vice President of Drug Discovery and Preclinical Development at RAPT Therapeutics. He joined the company in 2016 and has been instrumental in leading its efforts in discovering innovative drug solutions. With a distinguished career in the biotechnology and pharmaceutical sectors, David brings extensive expertise to his role, particularly in the development of treatments for various malignancies.
David Wustrow's Experience at RAPT Therapeutics
David Wustrow joined RAPT Therapeutics in 2016 and currently holds the position of Senior Vice President of Drug Discovery and Preclinical Development. His role encompasses guiding the company's research initiatives and steering the development of preclinical drug candidates. David's leadership continues to play a pivotal role in advancing the company's objectives in the pharmaceutical industry.
David Wustrow's Previous Role at Cleave Biosciences
Before joining RAPT Therapeutics, David Wustrow served as the Vice President of Chemical and Pharmaceutical Sciences at Cleave Biosciences. In this role, he directed chemistry efforts geared toward the discovery and development of first-in-class drug products aimed at treating solid and hematologic malignancies. His work at Cleave Biosciences laid the groundwork for several advancements in cancer treatment.
David Wustrow's Career at XenoPort and Beyond
David Wustrow held several significant positions at XenoPort, including Vice President, Medicinal Chemistry, and Executive Director of Scientific Assessment and Licensing. He has also worked as Executive Director of Chemistry at Neurogen and as Senior Director of Neuroscience Chemistry at Pfizer. At Pfizer, he led cross-functional teams in delivering preclinical development candidates addressing pain, inflammation, and psychiatric disorders.
David Wustrow's Education and Publications
David Wustrow holds a Ph.D. in Organic Synthesis from The University of Rochester and a B.S. from Pennsylvania State University. He is the author of over 40 peer-reviewed publications and holds more than 30 U.S. patents. His educational background and contributions to scientific literature underscore his expertise and impact in the field of drug discovery and development.